Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Deffered Revenue: 2024-2025

Historic Non-Current Deffered Revenue for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $268.9 million.

  • Kura Oncology's Non-Current Deffered Revenue was N/A to $268.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.9 million, marking a year-over-year change of. This contributed to the annual value of $253.9 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Kura Oncology's Non-Current Deffered Revenue is $268.9 million, which was up 6.47% from $252.5 million recorded in Q2 2025.
  • Kura Oncology's 5-year Non-Current Deffered Revenue high stood at $271.9 million for Q1 2025, and its period low was $252.5 million during Q2 2025.